Experts have found that women diagnosed with lesions of varying degrees of precursor of cervical cancer, due to the human papillomavirus (HPV), often suffer a re-infection by that virus a few months after the end of the treatment with which They eliminated the injuries, and despite the effectiveness of it.

For this reason, the experts gathered at the recently held I Forum Update Cancer Prevention in Cervix Castilla y León, have recommended the administration of HPV vaccine in women who have lesions caused by this virus, and especially if they also They have risk factors to develop cancer.

Experts recommend vaccinating women who have been treated for a lesion caused by HPV and have some risk factor to prevent a possible reinfection

Dr. Ángel García Iglesias, section head of the Gynecology Service of the Hospital Clínico Universitario de Salamanca, explained that more than 9% of the women treated in their service in recent years suffered a recurrence, and that in 18.70% of these patients vaginal lesions were detected after a hysterectomy 12 months after treatment.

Among the factors that increase the risk of a woman presenting a reinfection by HPV experts indicate: an age over 40 years, menopause, smoking, having taken contraceptives for a long period of time, having had pregnancies or abortions and a weakened immune system. Therefore, they recommend that all women who have been treated for a lesion caused by HPV and have one or more of these risk factors be vaccinated to prevent possible reinfection.

In terms of vaccinating women infected with HPV, specialists attending the Forum explained that according to the data obtained in studies in this regard, active infection would not be affected, for good or bad, by the administration of the vaccine ; However, they believe that this prophylactic measure could prevent future reinfections to the patient, so they recommend vaccination also in these cases.

Source: I Forum of Update in Cancer Prevention of Cervix Castilla y León

HPV: Prevention by Vaccination (November 2019).